(Q36835212)

16 August 2017

First thalidomide clinical trial in multiple myeloma: a decade (English)

1 reference

16 August 2017

0 references

1 reference

1

Frits van Rhee

0 references

Bart Barlogie

13

object named as

Bart Barlogie

1 reference

16 August 2017

6

Antje Hoering

1 reference

16 August 2017

4

Elias Anaissie

1 reference

16 August 2017

Madhav Dhodapkar

2

1 reference

16 August 2017

John D Shaughnessy

3

1 reference

16 August 2017

David Siegel

5

1 reference

16 August 2017

Jerome Zeldis

7

1 reference

16 August 2017

Bonnie Jenkins

8

1 reference

16 August 2017

Seema Singhal

9

1 reference

16 August 2017

Jayesh Mehta

10

1 reference

16 August 2017

John Crowley

11

1 reference

16 August 2017

Sundar Jagannath

12

1 reference

16 August 2017

language of work or name

English

0 references

publication date

23 May 2008

1 reference

16 August 2017

4

1 reference

based on heuristic

inferred from page(s)

published in

Blood

1 reference

16 August 2017

112

1 reference

16 August 2017

1035-1038

1 reference

16 August 2017

4

1 reference

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

The molecular classification of multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

A phase 2 study of bortezomib in relapsed, refractory myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

Antitumor activity of thalidomide in refractory multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

Estimation of failure probabilities in the presence of competing risks: new representations of old estimators

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

Duration of survival in patients with myeloma treated with thalidomide

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

Thalidomide and hematopoietic-cell transplantation for multiple myeloma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2515147

MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants

5 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18502827

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18502827

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2008-02-140954

1 reference

16 August 2017

1 reference

16 August 2017

1 reference